HBM HOLDINGS-B (02142) saw its shares rise more than 3%. As of the time of writing, the stock was up 3.34%, trading at HK$12.67, with a turnover of HK$30.48 million.
On the news front, on January 7, according to an announcement on HBM HOLDINGS's official WeChat account, the results for the 2025 grants under the major national science and technology innovation initiative "Research on the Prevention and Treatment of Cancer, Cardiovascular, Cerebrovascular, Respiratory, and Metabolic Diseases" (part of the National Science and Technology Innovation 2030 Megaproject) have been officially released.
A project titled "Research on the Pathogenesis of Pancreatic Cancer and New Paradigms for Clinical Precision Diagnosis and Treatment," jointly submitted by Shanghai Changhai Hospital as the lead institution with participation from HBM HOLDINGS, has been successfully approved for funding.
The company has consistently focused on the research and development of innovative antibody therapies for oncology and immune diseases.
Leveraging its proprietary fully human transgenic mouse platform, Harbour Mice®, as a technological cornerstone, the company has built a pipeline of over 20 products, including bispecific antibodies, multispecific antibodies, and antibody-drug conjugates (ADCs).
It has also established deep collaborations with numerous globally renowned pharmaceutical companies such as AstraZeneca, Pfizer, Bristol Myers Squibb, Otsuka Pharmaceutical, AbbVie, and Moderna, with its technical capabilities receiving broad recognition from partners.
Furthermore, the company's innovative therapies targeting markers such as CLDN18.2 and LIFR have already entered clinical stages or the application phase, infusing diverse momentum into its pancreatic cancer treatment portfolio.
